Seto T - Search Results

1

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer.

Nakagawa K, Nadal E, Garon EB, Nishio M, Seto T, Yamamoto N, Park K, Shih JY, Paz-Ares L, Frimodt-Moller B, Zimmermann AH, Wijayawardana S, Visseren-Grul C, Reck M. Nakagawa K, et al. Among authors: seto t. Clin Cancer Res. 2021 Oct 1;27(19):5258-5271. doi: 10.1158/1078-0432.CCR-21-0273. Clin Cancer Res. 2021. PMID: 34301751 Free PMC article. Clinical Trial.

2

UFT plus gemcitabine combination chemotherapy in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial.

Ichinose Y, Seto T, Semba H, Itoh K, Inoue Y, Tanaka F, Araki J, Tamanoi M, Yamamoto H, Iwamoto N. Ichinose Y, et al. Among authors: seto t. Br J Cancer. 2005 Oct 3;93(7):770-3. doi: 10.1038/sj.bjc.6602781. Br J Cancer. 2005. PMID: 16175186 Free PMC article. Clinical Trial.

3

Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.

Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, Ariyoshi Y, Fukuoka M. Ando M, et al. Among authors: seto t. J Clin Oncol. 2006 Jun 1;24(16):2549-56. doi: 10.1200/JCO.2005.04.9866. J Clin Oncol. 2006. PMID: 16735708

4

Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904).

Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, Shinkai T, Sawa T, Goto I, Semba H, Seto T, Ando M, Satoh T, Yoshimura N, Negoro S, Fukuoka M. Kudoh S, et al. Among authors: seto t. J Clin Oncol. 2006 Aug 1;24(22):3657-63. doi: 10.1200/JCO.2006.06.1044. J Clin Oncol. 2006. PMID: 16877734 Clinical Trial.

5

Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in 80 patients with non-small-cell lung cancer: a multi-institutional phase II trial.

Seto T, Ushijima S, Yamamoto H, Ito K, Araki J, Inoue Y, Semba H, Ichinose Y; Thoracic Oncology Group. Seto T, et al. Br J Cancer. 2006 Sep 18;95(6):717-21. doi: 10.1038/sj.bjc.6603319. Epub 2006 Aug 29. Br J Cancer. 2006. PMID: 16940982 Free PMC article. Clinical Trial.

6

Catheter drainage followed by the instillation of bleomycin to manage malignant pericardial effusion in non-small cell lung cancer: a multi-institutional phase II trial.

Maruyama R, Yokoyama H, Seto T, Nagashima S, Kashiwabara K, Araki J, Semba H, Ichinose Y. Maruyama R, et al. Among authors: seto t. J Thorac Oncol. 2007 Jan;2(1):65-8. doi: 10.1097/JTO.0b013e31802c8260. J Thorac Oncol. 2007. PMID: 17410012 Free article. Clinical Trial.

7

A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.

Kiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, Yamamoto N, Tsuboi M, Yokota S, Seto T, Jiang H, Nishio K, Saijo N, Fukuoka M. Kiura K, et al. Among authors: seto t. J Thorac Oncol. 2008 Apr;3(4):386-93. doi: 10.1097/JTO.0b013e318168d228. J Thorac Oncol. 2008. PMID: 18379357 Free article. Clinical Trial.

8

Tegafur-uracil plus gemcitabine combination chemotherapy in patients with advanced non-small cell lung cancer previously treated with platinum.

Seto T, Yamanaka T, Nakano M, Ota M, Maruyama R, Okamoto T, Wataya H, Uematsu K, Seki N, Eguchi K, Semba H, Ichinose Y. Seto T, et al. J Thorac Oncol. 2008 Jun;3(6):637-42. doi: 10.1097/JTO.0b013e318174e070. J Thorac Oncol. 2008. PMID: 18520804 Free article. Clinical Trial.

9

Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib.

Wataya H, Okamoto T, Maruyama R, Seto T, Yamazaki K, Tagawa T, Fukuyama S, Osoegawa A, Ikeda J, Nishimura M, Yamanaka T, Ichinose Y. Wataya H, et al. Among authors: seto t. Lung Cancer. 2009 Jun;64(3):341-5. doi: 10.1016/j.lungcan.2008.09.005. Epub 2008 Nov 7. Lung Cancer. 2009. PMID: 18995926

10

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Oncology Group. Mitsudomi T, et al. Among authors: seto t. Lancet Oncol. 2010 Feb;11(2):121-8. doi: 10.1016/S1470-2045(09)70364-X. Epub 2009 Dec 18. Lancet Oncol. 2010. PMID: 20022809 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

841 results

Search Page

Filters